

August 26<sup>th</sup>, 2014

VRL/SEC/NSE

**National Stock Exchange of India Ltd..**  
5<sup>th</sup> Floor, Exchange Plaza  
Bandra (E), Mumbai- 400 051

**Sub. : VENUS shake hands with TEVA Canada for an Upcoming Anti Cancer Drug**

Dear Sir/Madam,

This is to inform you that Venus Remedies Limited has recently entered in to a collaborative agreement with TEVA, one of the leading generic multinational company and the largest manufacturer of generic drugs in the world with more than 200,000 prescriptions filled each day, for a block buster Anti Cancer drug. This high potential drug is under patent protection till 2016 and is widely used for the treatment of malignant pleural mesothelioma and non-squamous non-small cell lung cancer having a market of more than \$4 billion and estimated to increase to \$5.4 billion by 2020 in the Regulated markets of United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

Under this collaboration, Venus Remedies Limited will be initially developing the drug in their Research Unit "Venus Medicine Research Center" for assisting TEVA in registrations. Thereafter, Venus will also use its manufacturing capability to support its valuable partner in enhancing the business in Canada market. The GMP granted to Venus for EU is also valid for Canada, based on which, Venus infrastructure and regulatory competence will be used for commercialization of this blockbuster drug in Canadian market.

The current global Anti Cancer market size is USD 130 Billion with the share of USD 2.8 Billion of this drug. Its market size in Canada alone is approximately \$ 75-100 Million and this association will be able to capture respectable market share of the product in 1<sup>st</sup> Year of Launch.

The Company is already in association with Teva for two Cephalosporins product business from EU market. Conclusion of the deal for Canada market has further strengthened its relationships as well as widened the scope of the company's products. With this

## VENUS REMEDIES LIMITED


### Corporate Office :

51-52, Industrial Area, Phase- I,  
Panchkula (Hry.) 134113, India

### Regd. Office :

SCO 857, Cabin No. 10, 2nd Floor, NAC,  
Manimajra, Chandigarh (U.T.) 160101, India

Website : [www.venusremedies.com](http://www.venusremedies.com)  
[www.venusmedicineresearchcentre.com](http://www.venusmedicineresearchcentre.com)



### Unit-I :

51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India  
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566

### Unit-II :

Hill Top Industrial Estate, Jharmajri EPIR Phase-I, (Extn.),  
Bhatoli Kalan, Baddi (H.P) 173205, India  
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272

### Unit-V :

VENUS PHARMA GmbH  
AM Bahnhof 1-3, D-59368, Werne, Germany

association, Venus will be penetrating Canadian market for the first time which will add another territory to VRL's quest for quality services. TEVA will use Venus' infrastructure and regulatory competence for commercialization of this anticancer product in Canadian market.

Yours faithfully,  
for VENUS REMEDIES LIMITED.

*Ramanjit*  
Ramanjit Kaur  
Deputy Manager  
Corporate Communication



## VENUS REMEDIES LIMITED


### Corporate Office :

51-52, Industrial Area, Phase- I,  
Panchkula (Hry.) 134113, India

### Regd. Office :

SCO 857, Cabin No. 10, 2nd Floor, NAC,  
Manimajra, Chandigarh (U.T.) 160101, India

Website : [www.venusremedies.com](http://www.venusremedies.com)  
[www.venusmedicineresearchcentre.com](http://www.venusmedicineresearchcentre.com)



### Unit-I :

51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India  
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566

### Unit-II :

Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),  
Bhatoli Kalan, Baddi (H.P.) 173205, India  
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272

### Unit-V :

VENUS PHARMA GmbH  
AM Bahnhof 1-3, D-59368, Werne, Germany